Chlamydia TrachomatisNCT07002047
Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in Germany
An observational study of Chlamydia Trachomatis, run by Sanofi at 1 site in Germany.
Trial summary
This study assesses the epidemiologic situation of chlamydia trachomatis, its complications and long term sequalae and related healthcare resource utilization and costs among adults in Germany. Read more about this study
- Who is it for?
- Ages 14 to 44 years
- Conditions the study is for
- Chlamydia Trachomatis
- How many people
- 81,239 participants
- Where
- 1 siteGermany
- Study dates
- 13 Mar 2025to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 to 44 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Adolescents and adults aged 14 to 44 years in the years 2008-2022 with documented (confirmed) diagnosis of CT.
Who may be able to join
- Either male or female is documented as gender in base data
- At cohort entry, a patient must be aged between 14 and 44 years
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
About this study
This study assesses the epidemiologic situation of chlamydia trachomatis, its complications and long term sequalae and related healthcare resource utilization and costs among adults in Germany.
The study is a retrospective cohort study based on German Statutory Health Insurance (SHI) claims data for adolescents and adults aged 14 to 44 years in the years 2008-2022 with documented (confirmed) diagnosis of CT.
Read more
Study Objectives are to:
- Estimate frequency of potential short-term complications and long-term sequelae in patients with medically attended chlamydia infection
- Analyze time from first documented prevalent CT infection to first potential complication/sequelae diagnosis
- Estimate frequency of re-infection (chlamydia recurrence) and co-infections with other sexually transmitted infections (STIs) in patients with medically-attended chlamydia infection
- Estimate absolute healthcare resource utilization (by level of care and specialty) and costs in patients with chlamydia infection, including for potential short-term complications and long-term sequelae
- Estimate administrative prevalence of medically-attended chlamydia infection in the overall study population
- Estimate administrative prevalence of diagnoses potentially associated with a chlamydia infection (i.e., short-term complications/long-term sequelae) in the overall study population
- Estimate frequency of chlamydia testing in the overall study population
- Conditions
- Chlamydia Trachomatis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Male and Female Adolescents and Adults with CT | Male and Female patients aged between 14 and 44 years of age with documented (confirmed) CT diagnosis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of female participants with documented (confirmed) outpatient or any inpatient of pelvic inflammatory disease (PID)
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Measured: From Year 2008 to Year 2022
Number of female participants with documented confirmed outpatient or any inpatient diagnosis of ectopic pregnancy
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Measured: From Year 2008 to Year 2022
Number of female participants with documented confirmed outpatient or any inpatient diagnosis tubal factor infertility
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Measured: From Year 2008 to Year 2022
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of orchitis or epididymitis
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Measured: From Year 2008 to Year 2022
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of proctitis
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Measured: From Year 2008 to Year 2022
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of prostatitis
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Measured: From Year 2008 to Year 2022
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of female/male infertility
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Measured: From Year 2008 to Year 2022
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of Urethritis and urethral syndrome
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Measured: From Year 2008 to Year 2022
Time in days from first documented prevalent CT infection to first documented complication/sequelae diagnosis
This time-to-event analysis will use the Kaplan-Meier method to estimate the median time-to-event in the presence of censoring
Measured: From Year 2008 to Year 2022
Number of male and female participants with confirmed outpatient or any inpatient CT diagnosis at least 30 days after last CT diagnosis of any kind (reinfection)
The absolute number of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases.
Measured: From Year 2008 to Year 2022
Number of CT reinfections/episodes
The absolute number of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases.
Measured: From Year 2008 to Year 2022
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of other STI
The absolute number of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases.
Measured: From Year 2008 to Year 2022
Cost incurred from the number of physician contacts (of any specialty)
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
Costs incurred from the number of hospital admissions
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
Costs incurred for the number of prescriptions filled for any drug
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
Costs incurred for the number of filled prescriptions for any medical aid
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
Costs incurred for the number of physician contacts (of any specialty) related to CT or STI-diagnoses.
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
Costs incurred for the number of hospital admissions related to CT or STI-diagnoses.
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
Costs incurred for the number of filled prescriptions for CT-related antibiotics, dispensed within 30 days after CT diagnosis
Costs are summed up per patient for the specified follow-up time and numbers for each ATC code will be reported separately and in aggregated form
Measured: From Year 2008 to Year 2022
Costs incurred for the number of filled prescriptions for medical aids related to CT or STI diagnoses
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
Total CT-/STI-unspecific health care costs (inpatient, outpatient, drugs, medical aids)
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
CT-/STI-unspecific outpatient costs
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
CT-/STI-unspecific inpatient costs
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
CT-/STI-unspecific drug cost
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
CT-/STI-unspecific medical aid costs
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
Outpatient costs that are related to cases with a confirmed CT diagnosis
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
Inpatient costs that are related to cases with any CT diagnosis
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
Outpatient costs that are related to cases with any confirmed STI diagnosis
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
Inpatient costs that are related to cases with any confirmed STI diagnosis
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
Costs of potentially CT-relevant antibiotics dispensed up to 30 days after confirmend outpatient or any inpatient CT diagnosis
Costs are summed up per patient for the specified follow-up time
Measured: From Year 2008 to Year 2022
Secondary outcomes (11)
Confirmed outpatient or any inpatient CT diagnosis
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Measured: From Year 2008 to Year 2022
Confirmed outpatient or any inpatient of PID (CT associated, or other origin) in females
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Measured: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of ectopic pregnancy in females
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Measured: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis tubal factor infertility in females
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Measured: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of orchitis or epididymitis in males
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Measured: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of proctitis in males
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Measured: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of prostatitis in males
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Measured: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of infertility in males
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Measured: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of Urethritis and urethral syndrome in males
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Measured: From Year 2008 to Year 2022
Number of male and female participants with documented CT test (screening)
The absolute number of tests as well as the absolute and relative frequency of tested individuals will be reported
Measured: From Year 2008 to Year 2022
Number of male and female participants with documented CT tests (diagnostic/curative)
The absolute number of tests as well as the absolute and relative frequency of tested individuals will be reported
Measured: From Year 2008 to Year 2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2025
- Study start13 Mar 2025
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chlamydia TrachomatisStudies of the same condition, open and under way.
- More trials run by SanofiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 81,239 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sanofi
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07002047
- Sponsor's protocol ID
- VAV00049
- Other IDs
- U1111-1320-4648
- Status last verified
- Apr 2026
- First submitted
- 23 May 2025
- Last updated
- 4 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers may request access to the study report and the statistical analysis plan. Access to patient-level data cannot be granted due to data protection regulations applicable to the processing of secondary data for health services research. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in Germany
- ClinicalTrials.gov ID
- NCT07002047
- Acronym / sponsor ID
- VAV00049
- Conditions
- Chlamydia Trachomatis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 81,239 participants (actual)
- Lead sponsor
- SanofiIndustry (pharma, biotech, devices)
- Study start
- 13 Mar 2025 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 3 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study assesses the epidemiologic situation of chlamydia trachomatis, its complications and long term sequalae and related healthcare resource utilization and costs among adults in Germany.
The study is a retrospective cohort study based on German Statutory Health Insurance (SHI) claims data for adolescents and adults aged 14 to 44 years in the years 2008-2022 with documented (confirmed) diagnosis of CT.
Study Objectives are to:
- Estimate frequency of potential short-term complications and long-term sequelae in patients with medically attended chlamydia infection
- Analyze time from first documented prevalent CT infection to first potential complication/sequelae diagnosis
- Estimate frequency of re-infection (chlamydia recurrence) and co-infections with other sexually transmitted infections (STIs) in patients with medically-attended chlamydia infection
- Estimate absolute healthcare resource utilization (by level of care and specialty) and costs in patients with chlamydia infection, including for potential short-term complications and long-term sequelae
- Estimate administrative prevalence of medically-attended chlamydia infection in the overall study population
- Estimate administrative prevalence of diagnoses potentially associated with a chlamydia infection (i.e., short-term complications/long-term sequelae) in the overall study population
- Estimate frequency of chlamydia testing in the overall study population
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Male and Female Adolescents and Adults with CT | – | –Male and Female patients aged between 14 and 44 years of age with documented (confirmed) CT diagnosis |
Who may qualify
- Ages
- 14 to 44 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Adolescents and adults aged 14 to 44 years in the years 2008-2022 with documented (confirmed) diagnosis of CT.
Key inclusion criteria (2 listed)
- Either male or female is documented as gender in base data
- At cohort entry, a patient must be aged between 14 and 44 years
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of female participants with documented (confirmed) outpatient or any inpatient of pelvic inflammatory disease (PID)
Time frame: From Year 2008 to Year 2022
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Number of female participants with documented confirmed outpatient or any inpatient diagnosis of ectopic pregnancy
Time frame: From Year 2008 to Year 2022
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Number of female participants with documented confirmed outpatient or any inpatient diagnosis tubal factor infertility
Time frame: From Year 2008 to Year 2022
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of orchitis or epididymitis
Time frame: From Year 2008 to Year 2022
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of proctitis
Time frame: From Year 2008 to Year 2022
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of prostatitis
Time frame: From Year 2008 to Year 2022
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of female/male infertility
Time frame: From Year 2008 to Year 2022
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of Urethritis and urethral syndrome
Time frame: From Year 2008 to Year 2022
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Time in days from first documented prevalent CT infection to first documented complication/sequelae diagnosis
Time frame: From Year 2008 to Year 2022
This time-to-event analysis will use the Kaplan-Meier method to estimate the median time-to-event in the presence of censoring
Number of male and female participants with confirmed outpatient or any inpatient CT diagnosis at least 30 days after last CT diagnosis of any kind (reinfection)
Time frame: From Year 2008 to Year 2022
The absolute number of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases.
Number of CT reinfections/episodes
Time frame: From Year 2008 to Year 2022
The absolute number of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases.
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of other STI
Time frame: From Year 2008 to Year 2022
The absolute number of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases.
Cost incurred from the number of physician contacts (of any specialty)
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
Costs incurred from the number of hospital admissions
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
Costs incurred for the number of prescriptions filled for any drug
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
Costs incurred for the number of filled prescriptions for any medical aid
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
Costs incurred for the number of physician contacts (of any specialty) related to CT or STI-diagnoses.
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
Costs incurred for the number of hospital admissions related to CT or STI-diagnoses.
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
Costs incurred for the number of filled prescriptions for CT-related antibiotics, dispensed within 30 days after CT diagnosis
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time and numbers for each ATC code will be reported separately and in aggregated form
Costs incurred for the number of filled prescriptions for medical aids related to CT or STI diagnoses
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
Total CT-/STI-unspecific health care costs (inpatient, outpatient, drugs, medical aids)
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
CT-/STI-unspecific outpatient costs
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
CT-/STI-unspecific inpatient costs
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
CT-/STI-unspecific drug cost
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
CT-/STI-unspecific medical aid costs
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
Outpatient costs that are related to cases with a confirmed CT diagnosis
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
Inpatient costs that are related to cases with any CT diagnosis
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
Outpatient costs that are related to cases with any confirmed STI diagnosis
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
Inpatient costs that are related to cases with any confirmed STI diagnosis
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
Costs of potentially CT-relevant antibiotics dispensed up to 30 days after confirmend outpatient or any inpatient CT diagnosis
Time frame: From Year 2008 to Year 2022
Costs are summed up per patient for the specified follow-up time
11 secondary outcomes
Confirmed outpatient or any inpatient CT diagnosis
Time frame: From Year 2008 to Year 2022
Confirmed outpatient or any inpatient of PID (CT associated, or other origin) in females
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of ectopic pregnancy in females
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis tubal factor infertility in females
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of orchitis or epididymitis in males
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of proctitis in males
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of prostatitis in males
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of infertility in males
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of Urethritis and urethral syndrome in males
Time frame: From Year 2008 to Year 2022
Number of male and female participants with documented CT test (screening)
Time frame: From Year 2008 to Year 2022
Number of male and female participants with documented CT tests (diagnostic/curative)
Time frame: From Year 2008 to Year 2022
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2026.
- Individual participant dataSharing planned: Yes. Qualified researchers may request access to the study report and the statistical analysis plan. Access to patient-level data cannot be granted due to data protection regulations applicable to the processing of secondary data for health services research. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Related trials for Chlamydia Trachomatis
RecruitingPhase 1
Phase 1 Study of Chlamydia Trachomatis mRNA Vaccine in Adults.
Chlamydia Trachomatis Immunization
Not yet recruiting
Optimizing Antibiotic Prescription in STI Clinics Using Rapid POCT
Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection
Not yet recruiting
Outcomes From Point-of-Care Sexually Transmitted Infection (STI) Testing in an Urban Sexual Health Clinic: A Randomized Trial
Neisseria Gonorrhoeae Infection, Chlamydia Trachomatis Infection
Recruiting
A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities
Chlamydia, Gonorrhea
Recruiting
Improving Maternal and Child Health Through Point-of-care STI Testing
Treponema Pallidum Infection, Chlamydia Trachomatis Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chlamydia Trachomatis, run by Sanofi at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of female participants with documented (confirmed) outpatient or any inpatient of pelvic inflammatory disease (PID) (time frame: From Year 2008 to Year 2022). The study lists 30 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.